The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus

• Published in: Diabetology international 2017-06, Vol.8 (2), p.218-227
• Main Authors: Bando, Yukihiro, Ogawa, Ayumi, Ishikura, Kazuhide, Kanehara, Hideo, Hisada, Azusa, Notumata, Kazuo, Okafuji, Kazuhiro, Toya, Daisyu
• Format: Article
• Language: English
• Subjects: Age; Alanine; Alanine transaminase; Body mass; Body mass index; Computed tomography; Diabetes; Diabetes mellitus; Endocrinology; Fatty liver; Hemoglobin; Liver; Medicine; Medicine & Public Health; Metabolic Diseases; Multiple regression analysis; Original; Original Article; Spleen; Steatosis; Tomography; Transaminase
• ISSN: 2190-1678; 2190-1686
• DOI: 10.1007/s13340-016-0302-y

We assessed the effects of a 12-week ipragliflozin treatment on the liver-to-spleen attenuation ratio ( L / S ratio) using computed tomography and on alanine transaminase (ALT) levels in Japanese patients with type 2 diabetes mellitus (T2DM). Sixty-two patients with T2DM [age, 56 ± 8 years; hemoglobin A1c (HbA1c) levels, 8.1 ± 0.9%; body mass index (BMI), 27.5 ± 3.3 kg/m 2 ] were randomly assigned in a 2:1 ratio to receive ipragliflozin (50 mg/day; ipragliflozin group; n  = 40) or continued treatment (control group; n  = 22) for 12 weeks. The primary endpoints were changes in ALT levels; the secondary endpoints included changes in the L / S ratio and in the visceral fat area (VFA) and subcutaneous fat area (SFA) before and after 12 weeks of the treatment as assessed by computed tomography. ALT levels (−12.45 vs. +5.82 IU/l, P